← Leaderboards
Paul Hergenrother
University Of Illinois Urbana-Champaign
$33,599,619
Attributed
$34,876,355
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,876,355 · 18
By mechanism
R01$25,436,387 · 10
T32$5,689,248 · 2
R35$2,064,080 · 1
R21$1,128,204 · 3
S10$558,436 · 2
Top collaborators
- Steven C. Zimmerman6 shared
- Anne M Baranger5 shared
- Brian T. Cunningham2 shared
Most similar at University Of Illinois Urbana-Champaign
Same institution · by research overlap
- Willem A Van Der Donk$17,237,843
- Neil L Kelleher$32,542,329
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationCellsSmall MoleculeProteinsIn VivoDesignBaseCessation Of LifeDrug KineticsCell Culture TechniquesTumorMalignant NeoplasmsPropertyCollectionIn VitroCancer CellAntineoplastic AgentsPharmaceutical PreparationsEnzymesResistanceSeriesMutationLeadExperimental Study
Grant awards (80)
Discovering accumulation guidelines and applying them to develop new antibiotics for Gram-negative pathogens$1,144,714
R01 · FY2025 · AI · contact PI
FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics$977,797
R01 · FY2025 · AI · contact PI
Developing a Suite of Targeted Anticancer Drugs$787,640
R35 · FY2025 · CA · contact PI
Training Program at the Chemistry Biology Interface$747,631
T32 · FY2025 · GM · contact PI
FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics$977,797
R01 · FY2024 · AI · contact PI
Developing a Suite of Targeted Anticancer Drugs$761,240
R35 · FY2024 · CA · contact PI
Training Program at the Chemistry Biology Interface$588,797
T32 · FY2024 · GM · contact PI
FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics$977,797
R01 · FY2023 · AI · contact PI
Training Program at the Chemistry Biology Interface$636,642
T32 · FY2023 · GM · contact PI
A Novel Therapeutic Strategy for Ovarian Cancer$587,174
R01 · FY2023 · CA · contact PI
Developing a Suite of Targeted Anticancer Drugs$515,200
R35 · FY2023 · CA · contact PI
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics$1,140,875
R01 · FY2022 · AI · contact PI
Training Program at the Chemistry Biology Interface$624,434
T32 · FY2022 · GM · contact PI
A Novel Therapeutic Strategy for Ovarian Cancer$597,841
R01 · FY2022 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$395,217
R01 · FY2022 · CA · contact PI
Targeted Therapy for Head and Neck Cancer$363,736
R01 · FY2022 · DE · contact PI
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics$1,140,875
R01 · FY2021 · AI · contact PI
Training Program at the Chemistry Biology Interface$585,155
T32 · FY2021 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$403,281
R01 · FY2021 · CA · contact PI
Targeted Therapy for Head and Neck Cancer$367,410
R01 · FY2021 · DE · contact PI
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics$1,140,875
R01 · FY2020 · AI · contact PI
Training Program at the Chemistry Biology Interface$578,467
T32 · FY2020 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$403,284
R01 · FY2020 · CA · contact PI
Targeted Therapy for Head and Neck Cancer$367,410
R01 · FY2020 · DE · contact PI
Defining Parameters for Compound Accumulation in Gram-Negative Pathogens$265,608
R01 · FY2020 · GM · contact PI
Defining Parameters for Compound Accumulation in Gram Negative Pathogens$78,706
R01 · FY2020 · GM · contact PI
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics$1,140,875
R01 · FY2019 · AI · contact PI
Training Program at the Chemistry-Biology Interface$435,387
T32 · FY2019 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$391,184
R01 · FY2019 · CA · contact PI
Targeted Therapy for Head and Neck Cancer$367,410
R01 · FY2019 · DE · contact PI
Defining Parameters for Compound Accumulation in Gram-Negative Pathogens$276,137
R01 · FY2019 · GM · contact PI
Cytation 5 Cell Imaging Multi-Mode Reader$259,158
S10 · FY2019 · OD · contact PI
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics$1,436,141
R01 · FY2018 · AI · contact PI
Training Program at the Chemistry-Biology Interface$565,559
T32 · FY2018 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$417,934
R01 · FY2018 · CA · contact PI
Targeted Therapy for Head and Neck Cancer$367,410
R01 · FY2018 · DE · contact PI
Defining Parameters for Compound Accumulation in Gram-Negative Pathogens$280,906
R01 · FY2018 · GM · contact PI
Identification of inhibitors of poly (ADP-ribose) glycohydrolase (PARG)$193,752
R21 · FY2018 · CA · contact PI
Training Program at the Chemistry-Biology Interface$466,115
T32 · FY2017 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$432,711
R01 · FY2017 · CA · contact PI
Defining Parameters for Compound Accumulation in Gram-Negative Pathogens$329,452
R01 · FY2017 · GM · contact PI
Identification of inhibitors of poly (ADP-ribose) glycohydrolase (PARG)$159,642
R21 · FY2017 · CA · contact PI
Training Program at the Chemistry-Biology Interface$461,061
T32 · FY2016 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$442,139
R01 · FY2016 · CA · contact PI
A novel strategy to overcome resistance in Temozolomide-Refractory Glioblastomas$199,553
R21 · FY2016 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$451,299
R01 · FY2015 · CA · contact PI
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors$421,493
R01 · FY2015 · GM · contact PI
A novel strategy to overcome resistance in Temozolomide-Refractory Glioblastomas$179,619
R21 · FY2015 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$446,391
R01 · FY2014 · CA · contact PI
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors$423,781
R01 · FY2014 · GM · contact PI
Design synthesis and evaluation of lactate dehydrogenase inhibitors$73,243
R01 · FY2014 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$451,618
R01 · FY2013 · CA · contact PI
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors$411,264
R01 · FY2013 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$289,790
R01 · FY2013 · AR
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors$460,019
R01 · FY2012 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$305,043
R01 · FY2012 · AR
Small Molecule Activators of Procaspases as Anti-Cancer Agents$469,696
R01 · FY2011 · CA · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$305,043
R01 · FY2011 · AR
Development of Distributed Feedback Laser Biosensor Technology as a High Resoluti$248,466
R21 · FY2011 · EB
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$317,753
R01 · FY2010 · AR
COMBATING MULTI-DRUG RESISTANT BACTERIA$299,524
R01 · FY2010 · GM · contact PI
A Walk-UP LC-MS for the Rapid Analysis of Organic Compounds$299,278
S10 · FY2010 · RR · contact PI
Small Molecule Activators of Procaspases as Anti-cancer Agents$263,110
R01 · FY2010 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$221,535
R01 · FY2010 · CA · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$152,231
R01 · FY2010 · AR
Development of Distributed Feedback Laser Biosensor Technology as a High Resoluti$147,172
R21 · FY2010 · EB
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$320,963
R01 · FY2009 · AR
Small Molecule Activators of Procaspases as Anti-Cancer Agents$304,846
R01 · FY2009 · CA · contact PI
COMBATING MULTI-DRUG RESISTANT BACTERIA$299,524
R01 · FY2009 · GM · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$221,945
R01 · FY2009 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$222,342
R01 · FY2008 · CA · contact PI
Small Molecule Activators of Procaspases as Anti-Cancer Agents$260,728
R01 · FY2007 · CA · contact PI
Combating Mult-Drug Resistant Bacteria$194,551
R01 · FY2007 · GM · contact PI
Combating Mult-Drug Resistant Bacteria$51,538
R01 · FY2007 · GM · contact PI
Combating Mult-Drug Resistant Bacteria$26,000
R01 · FY2007 · GM · contact PI
Combating Mult-Drug Resistant Bacteria$200,619
R01 · FY2006 · GM · contact PI
Combating Mult-Drug Resistant Bacteria$205,702
R01 · FY2005 · GM
Combating Mult-Drug Resistant Bacteria$73,553
R01 · FY2004 · GM
Combating Mult-Drug Resistant Bacteria$12,000
R01 · FY2004 · GM
Combating Mult-Drug Resistant Bacteria$66,547
R01 · FY2003 · GM